Skip to Content
Merck
CN

Key Documents

View All Documentation

M-128

Mirtazapine solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C17H19N3
CAS Number:
85650-52-8
Molecular Weight:
265.35
NACRES:
NA.24
UNSPSC Code:
41116107
EC Number:
200-659-6
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

CN1CCN2C(C1)c3ccccc3Cc4cccnc24

InChI

1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3

InChI key

RONZAEMNMFQXRA-UHFFFAOYSA-N

Gene Information

human ... ADRA2A(150), ADRA2B(151), ADRA2C(152), HTR2A(3356), HTR2C(3358)

General description

Mirtazapine is a tetracyclic antidepressant marketed under the trade names Remeron®, Avanza, or Zispin for treatment of depression. This Certified Spiking Solution® is suitable for LC/MS or GC/MS applications in forensic analysis, clinical toxicology, or urine drug testing.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Remeron is a registered trademark of MSD
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Supply conditions do not apply to the regions and states of Brazil: North, Northeast, Mato Grosso do Sul, Mato Grosso, and Rio Grande do Sul.

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes

Storage Class

3 - Flammable liquids

wgk

WGK 1

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Regulatory Information

危险化学品

This item has

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

LC-MS Analysis of Serum for a Wide Analyte Range Using a Novel HLB SPE Phase

Analysis of 20 pharmaceutical compounds in calf serum using Supel™ Swift HLB SPE cartridge for cleanup and LC-MS determination and another commercially available HLB cartridge for comparison.

Seda G Sagdinc et al.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 104, 222-234 (2012-12-26)
Mirtazapine (±)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine is a compound with antidepressant therapeutic effects. It is the 6-aza derivative of the tetracyclic antidepressant mianserin (±)-2-methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine. The FT-IR and FT-Raman spectra of mirtazapine have been recorded in 4000-400 cm(-1) and 3500-10 cm(-1), respectively. The optimized geometry
Xiaoyu Liu et al.
Neurochemical research, 38(9), 1973-1979 (2013-07-10)
Chemotherapic drugs may elicit acute or chronic peripheral neuropathies. Mirtazapine, as an antidepressant, is also used for the treatment of neuropathic pain. The current study aimed to investigate the effect of mirtazapine on the oxaliplatin-induced neuropathy in rats as well
Steven M Graves et al.
Pharmacology & therapeutics, 136(3), 343-353 (2012-09-11)
Understanding substance use disorders (SUDs) and the problems associated with abstinence has grown in recent years. Nonetheless, highly efficacious treatment targeting relapse prevention has remained elusive, and there remains no FDA-approved pharmacotherapy for psychostimulant dependence. Preclinical and clinical investigations assessing
View All Related Papers

Global Trade Item Number

SKUGTIN
M-128-1ML04061833976814